AnHeart Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 140

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $397M

  • Investors
  • 1

AnHeart Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to improve the lives of cancer patients. The company develops a pipeline of novel precision therapies for people with cancer, enabling medical professionals to improve human health and quality of life with required medical advancements.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 777 Third Avenue
  • Suite 1704
  • New York, NY 10017
  • United States
+1 (212)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Vertical(s)
Corporate Office
  • 777 Third Avenue
  • Suite 1704
  • New York, NY 10017
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AnHeart Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 09-Apr-2024 $397M Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 01-Sep-2021 Completed Pre-Clinical Trials
2. Early Stage VC (Series A1) 10-Aug-2020 $24M $39M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 15-May-2019 $15M $15M Completed Pre-Clinical Trials
To view AnHeart Therapeutics’s complete valuation and funding history, request access »

AnHeart Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to improve the lives of cancer patients. The company develops a pipelin
Biotechnology
New York, NY
140 As of 2024

Hayward, CA
 

Newark, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AnHeart Therapeutics Competitors (3)

One of AnHeart Therapeutics’s 3 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arcus Biosciences Formerly VC-backed Hayward, CA
Rain Oncology Formerly VC-backed Newark, CA
Cellectar Biosciences Formerly Accelerator/Incubator backed Florham Park, NJ
You’re viewing 3 of 3 competitors. Get the full list »

AnHeart Therapeutics Patents

AnHeart Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025045203-A1 Heterocyclic compound, and intermediate and use thereof Inactive 01-Sep-2023
JP-2025515952-A Method for preparing 3,6-disubstituted imidazo[1,2-b]pyridazine compounds Pending 18-May-2022
WO-2023220967-A1 Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds Inactive 18-May-2022
CA-3223035-A1 Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof Pending 01-Jul-2021
WO-2023272701-A1 Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof Inactive 01-Jul-2021 C07D487/04
To view AnHeart Therapeutics’s complete patent history, request access »

AnHeart Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AnHeart Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cenova Capital Venture Capital Minority
China Merchants Venture Capital Corporate Venture Capital Minority
Decheng Capital Venture Capital Minority
Fuzhuo Investment Venture Capital Minority
Innovent Biologics Corporation Minority
You’re viewing 5 of 11 investors. Get the full list »

AnHeart Therapeutics FAQs

  • When was AnHeart Therapeutics founded?

    AnHeart Therapeutics was founded in 2018.

  • Where is AnHeart Therapeutics headquartered?

    AnHeart Therapeutics is headquartered in New York, NY.

  • What is the size of AnHeart Therapeutics?

    AnHeart Therapeutics has 140 total employees.

  • What industry is AnHeart Therapeutics in?

    AnHeart Therapeutics’s primary industry is Biotechnology.

  • Is AnHeart Therapeutics a private or public company?

    AnHeart Therapeutics is a Private company.

  • What is the current valuation of AnHeart Therapeutics?

    The current valuation of AnHeart Therapeutics is .

  • What is AnHeart Therapeutics’s current revenue?

    The current revenue for AnHeart Therapeutics is .

  • How much funding has AnHeart Therapeutics raised over time?

    AnHeart Therapeutics has raised $100M.

  • Who are AnHeart Therapeutics’s investors?

    Cenova Capital, China Merchants Venture Capital, Decheng Capital, Fuzhuo Investment, and Innovent Biologics are 5 of 11 investors who have invested in AnHeart Therapeutics.

  • Who are AnHeart Therapeutics’s competitors?

    Arcus Biosciences, Rain Oncology, and Cellectar Biosciences are competitors of AnHeart Therapeutics.

  • When was AnHeart Therapeutics acquired?

    AnHeart Therapeutics was acquired on 09-Apr-2024.

  • Who acquired AnHeart Therapeutics?

    AnHeart Therapeutics was acquired by Nuvation Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process